Alpha adrenergic antagonist: Difference between revisions
imported>Robert Badgett mNo edit summary |
imported>Robert Badgett (→Costs: Added costs for Doxazosin) |
||
| Line 8: | Line 8: | ||
According to drugstore.com: | According to drugstore.com: | ||
* [[Alfuzosin]] (Uroxatral) 10 mg - $121.85 for 30 tablets | * [[Alfuzosin]] (Uroxatral) 10 mg - $121.85 for 30 tablets | ||
* [[ | * [[Doxazosin]] (Cardura) 8 mg - $23.99 for 30 tablets | ||
* [[Naftopidil]] | * [[Naftopidil]] | ||
* [[Prazosin]] (Minipress) 5 mg - $33.99 for ''60'' tablets | * [[Prazosin]] (Minipress) 5 mg - $33.99 for ''60'' tablets | ||
Revision as of 12:58, 18 March 2010
In pharmacology, alpha adrenergic blockers are "drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma."[1] They are also used for benign prostatic hyperplasia.
Naftopidil is more selective for the alpha-1a adrenergic receptor and has been used to treat benign prostatic hyperplasia.[2] Vascular drug toxicity may be less with tamsulosin due to more selectivity to α1-A and α1-D adrenergic receptors according to a meta-analysis supported by Boehringer Ingelheim Pharmaceuticals, the maker of tamsulosin.[3]
Costs
According to drugstore.com:
- Alfuzosin (Uroxatral) 10 mg - $121.85 for 30 tablets
- Doxazosin (Cardura) 8 mg - $23.99 for 30 tablets
- Naftopidil
- Prazosin (Minipress) 5 mg - $33.99 for 60 tablets
- Tamsulosin (Flomax) 0.4 - $142.19 for 30 tablets
- Terazosin
References
- ↑ Anonymous (2024), Alpha adrenergic antagonist (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Garimella PS, Fink HA, Macdonald R, Wilt TJ (2009). "Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.". Cochrane Database Syst Rev (4): CD007360. DOI:10.1002/14651858.CD007360.pub2. PMID 19821408. Research Blogging.
- ↑ Nickel JC, Sander S, Moon TD (2008). "A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia.". Int J Clin Pract 62 (10): 1547-59. DOI:10.1111/j.1742-1241.2008.01880.x. PMID 18822025. PMC PMC2658011. Research Blogging.